Megalin/LRP2 expression is induced by peroxisome proliferator-activated receptor -alpha and -gamma: Implications for PPARs' roles in renal function

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Cabezas, Felipe ^a   Lagos, Jonathan ^a   Céspedes, Carlos ^a   Vio, Carlos P ^a   Bronfman, Miguel ^a   Marzolo, María Paz ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

MEGALIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INTERSTITIAL NEPHRITIS; KIDNEY FUNCTION; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; RAT; RECEPTOR BINDING; RECEPTOR UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; CELL CULTURE; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; SPRAGUE DAWLEY RAT; UPREGULATION;

BOVINAE; RATTUS;

ANIMALS; BASE SEQUENCE; BINDING SITES; CELLS, CULTURED; GENE EXPRESSION REGULATION; HUMANS; KIDNEY; LDL-RECEPTOR RELATED PROTEIN 2; LIGANDS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PPAR ALPHA; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; UP-REGULATION;

EID: 79551651167     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016794     Document Type: Article

References (98)

1. Herz J, Bock HH (2002) Lipoprotein receptors in the nervous system. Annu Rev Biochem 71: 405-434.
2. Marino M, Pinchera A, McCluskey RT, Chiovato L (2001) Megalin in thyroid physiology and pathology. Thyroid 11: 47-56.
3. Erranz B, Miquel JF, Argraves WS, Barth JL, Pimentel F, et al. (2004) Megalin and cubilin expression in gallbladder epithelium and regulation by bile acids. J Lipid Res 45: 2185-2198.
4. Willnow TE, Hilpert J, Armstrong SA, Rohlmann A, Hammer RE, et al. (1996) Defective forebrain development in mice lacking gp330/megalin. Proc Natl Acad Sci U S A 93: 8460-8464.
5. Spoelgen R, Hammes A, Anzenberger U, Zechner D, Andersen OM, et al. (2005) LRP2/megalin is required for patterning of the ventral telencephalon. Development 132: 405-414.
6. Li Y, Lu W, Marzolo MP, Bu G (2001) Differential functions of members of the low density lipoprotein receptor family suggested by their distinct endocytosis rates. J Biol Chem 276: 18000-18006.
7. Marzolo MP, Yuseff MI, Retamal C, Donoso M, Ezquer F, et al. (2003) Differential distribution of low-density lipoprotein-receptor-related protein (LRP) and megalin in polarized epithelial cells is determined by their cytoplasmic domains. Traffic 4: 273-288.
8. Yuseff MI, Farfan P, Bu G, Marzolo MP (2007) A cytoplasmic PPPSP motif determines megalin's phosphorylation and regulates receptor's recycling and surface expression. Traffic 8: 1215-1230.
9. Christensen EI, Verroust PJ (2002) Megalin and cubilin, role in proximal tubule function and during development. Pediatr Nephrol 17: 993-999.
10. McCarthy RA, Argraves WS (2003) Megalin and the neurodevelopmental biology of sonic hedgehog and retinol. J Cell Sci 116: 955-960.
11. Maurer ME, Cooper JA (2005) Endocytosis of megalin by visceral endoderm cells requires the Dab2 adaptor protein. J Cell Sci 118: 5345-5355.
12. Cui S, Verroust PJ, Moestrup SK, Christensen EI (1996) Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol 271: F900-907.
13. Kantarci S, Al-Gazali L, Hill RS, Donnai D, Black GC, et al. (2007) Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai- Barrow and facio-oculo-acoustico-renal syndromes. Nat Genet 39: 957-959.
14. Lee BH, Lee SH, Choi HJ, Kang HG, Oh SW, et al. (2009) Decreased renal uptake of (99m)Tc-DMSA in patients with tubular proteinuria. Pediatr Nephrol 24: 2211-2216.
15. Ambjorn M, Asmussen JW, Lindstam M, Gotfryd K, Jacobsen C, et al. (2008) Metallothionein and a peptide modeled after metallothionein, EmtinB, induce neuronal differentiation and survival through binding to receptors of the lowdensity lipoprotein receptor family. J Neurochem 104: 21-37.
16. Chung RS, Penkowa M, Dittmann J, King CE, Bartlett C, et al. (2008) Redefining the role of metallothionein within the injured brain: extracellular metallothioneins play an important role in the astrocyte-neuron response to injury. J Biol Chem 283: 15349-15358.
17. Vinuesa E, Sola A, Jung M, Alfaro V, Hotter G (2008) Lipocalin-2-induced renal regeneration depends on cytokines. Am J Physiol Renal Physiol 295: F1554-1562.
18. Pedersen MO, Jensen R, Pedersen DS, Skjolding AD, Hempel C, et al. (2009) Metallothionein-I+II in neuroprotection. Biofactors 35: 315-325.
19. Fleming CE, Mar FM, Franquinho F, Saraiva MJ, Sousa MM (2009) Transthyretin internalization by sensory neurons is megalin mediated and necessary for its neuritogenic activity. J Neurosci 29: 3220-3232.
20. Fujigaki Y, Sakakima M, Sun Y, Fujikura T, Tsuji T, et al. (2009) Cell division and phenotypic regression of proximal tubular cells in response to uranyl acetate insult in rats. Nephrol Dial Transplant 24: 2686-2692.
21. Christensen EI, Birn H, Verroust P, Moestrup SK (1998) Megalin-mediated endocytosis in renal proximal tubule. Ren Fail 20: 191-199.
22. Hama H, Saito A, Takeda T, Tanuma A, Xie Y, et al. (2004) Evidence indicating that renal tubular metabolism of leptin is mediated by megalin but not by the leptin receptors. Endocrinology 145: 3935-3940.
23. Gonzalez-Villalobos R, Klassen RB, Allen PL, Navar LG, Hammond TG (2005) Megalin binds and internalizes angiotensin II. Am J Physiol Renal Physiol 288: F420-427.
24. Gonzalez-Villalobos R, Klassen RB, Allen PL, Johanson K, Baker CB, et al. (2006) Megalin binds and internalizes angiotensin-(1-7). Am J Physiol Renal Physiol 290: F1270-1275.
25. Orlando RA, Rader K, Authier F, Yamazaki H, Posner BI, et al. (1998) Megalin is an endocytic receptor for insulin. J Am Soc Nephrol 9: 1759-1766.
26. Tojo A, Onozato ML, Ha H, Kurihara H, Sakai T, et al. (2001) Reduced albumin reabsorption in the proximal tubule of early-stage diabetic rats. Histochem Cell Biol 116: 269-276.
27. Tojo A, Onozato ML, Kurihara H, Sakai T, Goto A, et al. (2003) Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. Hypertens Res 26: 413-419.
28. Odera K, Goto S, Takahashi R (2007) Age-related change of endocytic receptors megalin and cubilin in the kidney in rats. Biogerontology 8: 505-515.
29. Czekay RP, Orlando RA, Woodward L, Adamson ED, Farquhar MG (1995) The expression of megalin (gp330) and LRP diverges during F9 cell differentiation. J Cell Sci 108: 1433-1441.
30. Liu W, Yu WR, Carling T, Juhlin C, Rastad J, et al. (1998) Regulation of gp330/megalin expression by vitamins A and D. Eur J Clin Invest 28: 100-107.
31. Hosojima M, Sato H, Yamamoto K, Kaseda R, Soma T, et al. (2009) Regulation of megalin expression in cultured proximal tubule cells by angiotensin II type 1A receptor- and insulin-mediated signaling cross-talk. Endocrinology 150: 871-878.
32. Caruso-Neves C, Pinheiro AA, Cai H, Souza-Menezes J, Guggino WB (2006) PKB and megalin determine the survival or death of renal proximal tubule cells. Proc Natl Acad Sci U S A 103: 18810-18815.
33. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137: 354-366.
34. IJpenberg A, Jeannin E, Wahli W, Desvergne B (1997) Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/ retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem 272: 20108-20117.
35. Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94: 4312-4317.
36. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, et al. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 94: 4318-4323.
37. Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, et al. (2008) Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat Struct Mol Biol 15: 924-931.
38. Guan Y (2004) Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 15: 2801-2815.
39. Gauthier A, Vassiliou G, Benoist F, McPherson R (2003) Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor c. J Biol Chem 278: 11945-11953.
40. Rakhshandehroo M, Hooiveld G, Muller M, Kersten S (2009) Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One 4: e6796.
41. Guan Y, Zhang Y, Davis L, Breyer MD (1997) Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 273: F1013-1022.
42. Yang T, Michele DE, Park J, Smart AM, Lin Z, et al. (1999) Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 277: F966-973.
43. Zafiriou S, Stanners SR, Polhill TS, Poronnik P, Pollock CA (2004) Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. Kidney Int 65: 1647-1653.
44. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G (2005) Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45: 485-493.
45. Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, et al. (2006) PPAR-{alpha} and {gamma} agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 21: 2399-2405.
46. Park CW, Zhang Y, Zhang X, Wu J, Chen L, et al. (2006) PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69: 1511-1517.
47. Shibata T, Takeuchi S, Yokota S, Kakimoto K, Yonemori F, et al. (2000) Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT- 501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol 130: 495-504.
48. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, et al. (2001) Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 50: 1193-1196.
49. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, et al. (2000) Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 14: 250-254.
50. Toblli JE, Ferrini MG, Cao G, Vernet D, Angerosa M, et al. (2009) Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol Dial Transplant 24: 2384-2391.
51. Miyazaki Y, Cersosimo E, Triplitt C, Defronzo RA (2007) Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 72: 1367-1373.
52. Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, et al. (1998) Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 21: 2135-2139.
53. Al-Rasheed NM, Chana RS, Baines RJ, Willars GB, Brunskill NJ (2004) Ligandindependent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity. J Biol Chem 279: 49747-49754.
54. Letavernier E, Perez J, Joye E, Bellocq A, Fouqueray B, et al. (2005) Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol 16: 2395-2402.
55. Giral H, Villa-Bellosta R, Catalan J, Sorribas V (2007) Cytotoxicity of peroxisome proliferator-activated receptor alpha and gamma agonists in renal proximal tubular cell lines. Toxicol In Vitro 21: 1066-1076.
56. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, et al. (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43: 993-1002.
57. Schupp M, Janke J, Clasen R, Unger T, Kintscher U (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054-2057.
58. Eddy AA (1989) Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol 135: 719-733.
59. Thomas ME, Brunskill NJ, Harris KP, Bailey E, Pringle JH, et al. (1999) Proteinuria induces tubular cell turnover: A potential mechanism for tubular atrophy. Kidney Int 55: 890-898.
60. Ardiles LG, Loyola F, Ehrenfeld P, Burgos ME, Flores CA, et al. (2006) Modulation of renal kallikrein by a high potassium diet in rats with intense proteinuria. Kidney Int 69: 53-59.
61. Leheste JR, Rolinski B, Vorum H, Hilpert J, Nykjaer A, et al. (1999) Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 155: 1361-1370.
62. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, et al. (1999) An endocytic pathway essential for renal uptake and activation of the steroid 25- (OH) vitamin D3. Cell 96: 507-515.
63. Watanabe T (2004) Megalin and proximal renal tubular dysfunction in Dent disease. Pediatr Nephrol 19: 1305; author reply 1306.
64. Guggino SE (2007) Mechanisms of disease: what can mouse models tell us about the molecular processes underlying Dent disease? Nat Clin Pract Nephrol 3: 449-455.
65. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, et al. (2005) Molecular Characterization of New Selective Peroxisome Proliferator-Activated Receptor {gamma} Modulators With Angiotensin Receptor Blocking Activity. Diabetes 54: 3442-3452.
66. Hayden MR, Habibi J, Whaley-Connell A, Sowers D, Johnson M, et al. (2010) Nebivolol attenuates maladaptive proximal tubule remodeling in transgenic rats. Am J Nephrol 31: 262-272.
67. Banks T, Oyekan A (2008) Peroxisome proliferator-activated receptor alpha activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat. J Hypertens 26: 468-477.
68. Park CW, Kim HW, Ko SH, Chung HW, Lim SW, et al. (2006) Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 55: 885-893.
69. Fang HL, Strom SC, Cai H, Falany CN, Kocarek TA, et al. (2005) Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol Pharmacol 67: 1257-1267.
70. Yang Q, Nagano T, Shah Y, Cheung C, Ito S, et al. (2008) The PPAR alphahumanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol Sci 101: 132-139.
71. Chinetti G, Fruchart JC, Staels B (2000) Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49: 497-505.
72. Chinetti-Gbaguidi G, Fruchart JC, Staels B (2005) Pleiotropic effects of fibrates. Curr Atheroscler Rep 7: 396-401.
73. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, et al. (2000) CLA- 1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101: 2411-2417.
74. Mardones P, Pilon A, Bouly M, Duran D, Nishimoto T, et al. (2003) Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. J Biol Chem 278: 7884-7890.
75. Rokos CL, Ledwith BJ (1997) Peroxisome proliferators activate extracellular signal-regulated kinases in immortalized mouse liver cells. J Biol Chem 272: 13452-13457.
76. Gardner OS, Dewar BJ, Graves LM (2005) Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Mol Pharmacol 68: 933-941.
77. Li R, Zheng W, Pi R, Gao J, Zhang H, et al. (2007) Activation of peroxisome proliferator-activated receptor-alpha prevents glycogen synthase 3beta phosphorylation and inhibits cardiac hypertrophy. FEBS Lett 581: 3311-3316.
78. Bulhak AA, Jung C, Ostenson CG, Lundberg JO, Sjoquist PO, et al. (2009) PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway. Am J Physiol Heart Circ Physiol 296: H719-727.
79. Zou Z, Chung B, Nguyen T, Mentone S, Thomson B, et al. (2004) Linking receptor-mediated endocytosis and cell signaling: evidence for regulated intramembrane proteolysis of megalin in proximal tubule. J Biol Chem 279: 34302-34310.
80. Wolf G (2006) Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 70: 1914-1919.
81. Wolf G, Ziyadeh FN (2006) Leptin and renal fibrosis. Contrib Nephrol 151: 175-183.
82. Kumpers P, Gueler F, Rong S, Mengel M, Tossidou I, et al. (2007) Leptin is a coactivator of TGF-beta in unilateral ureteral obstructive kidney disease. Am J Physiol Renal Physiol 293: F1355-1362.
83. Carvajal G, Rodriguez-Vita J, Rodrigues-Diez R, Sanchez-Lopez E, Ruperez M, et al. (2008) Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int 74: 585-595.
84. Oyama Y, Takeda T, Hama H, Tanuma A, Iino N, et al. (2005) Evidence for megalin-mediated proximal tubular uptake of L-FABP, a carrier of potentially nephrotoxic molecules. Lab Invest 85: 522-531.
85. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, et al. (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71: 31-38.
86. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Koide H (2006) Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev 22: 385-389.
87. Dietrich MO, Spuch C, Antequera D, Rodal I, de Yebenes JG, et al. (2007) Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol Aging.
88. Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I (2005) Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J Neurosci 25: 10884-10893.
89. Pan GD, Wu H, Liu JW, Cheng NS, Xiong XZ, et al. (2005) Effect of peroxisome proliferator-activated receptor-gamma ligand on inflammation of human gallbladder epithelial cells. World J Gastroenterol 11: 6061-6065.
90. Mysiorek C, Culot M, Dehouck L, Derudas B, Staels B, et al. (2009) Peroxisomeproliferator- activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier. Curr Neurovasc Res 6: 181-193.
91. Roberts TJ, Chapman AC, Cipolla MJ (2009) PPAR-gamma agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension. Am J Physiol Heart Circ Physiol 297: H1347-1353.
92. Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M (2005) Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp Cell Res 304: 91-104.
93. Cimini A, Benedetti E, Cristiano L, Sebastiani P, D'Amico MA, et al. (2005) Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 130: 325-337.
94. Knutson A, Hellman P, Akerstrom G, Westin G (1998) Characterization of the human Megalin/LRP-2 promoter in vitro and in primary parathyroid cells. DNA Cell Biol 17: 551-560.
95. Stanton BA, Koeppen B (2004) The kidney; Berne R, Levi M, Koeppen B, Stanton BA, eds. St. Louis, MO.
96. Vio CP, An SJ, Cespedes C, McGiff JC, Ferreri NR (2001) Induction of cyclooxygenase-2 in thick ascending limb cells by adrenalectomy. J Am Soc Nephrol 12: 649-658.
97. Madeddu P, Vio CP, Straino S, Salis MB, Milia AF, et al. (2001) Renal phenotype of low kallikrein rats. Kidney Int 59: 2233-2242.
98. Salas SP, Giacaman A, Romero W, Downey P, Aranda E, et al. (2007) Pregnant rats treated with a serotonin precursor have reduced fetal weight and lower plasma volume and kallikrein levels. Hypertension 50: 773-779.